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Since its discovery the role of Neogenin, a multifunctional receptor implicated in 
proliferation, differentiation and migration, has been most frequently reported in 
neuronal development. However, recent studies have hinted that this receptor may 
play a role in other tissues and processes, from cell-fate decisions of embryonic 
stem cells to inflammation. We found Neogenin to be one of only two genes most 
frequently reported as deregulated in hematopoietic stem cell aging. We show here 
that Neogenin expression is positively correlated with self-renewal potential of 
murine hematopoietic stem and progenitor cells, and is highly enriched in LT-HSC. 
By knocking-down Neogenin, we demonstrate for the first time that it is required for 
functioning of aged HSC, both in vivo and in vitro. In humans, Neogenin is highly 
expressed on a subset of cord-blood derived HSCs. These Neogeninhi cells have 
reduced stem-cell potential when tested in vitro. Overall, our data show that Neogenin 
expression is able to distinguish HSC subsets with different stem cell potential and 
that knock-down of Neogenin expression affects proliferation and repopulating ability 
of HSCs. These results highlight Neogenin as an important receptor for hematopoietic 
stem cell function and aging. 
Introduction
Although many studies have reported deregulation of gene expression with aging of 
hematopoietic stem cells (HSCs), we have previously shown that there is very little 
overlap in gene lists between studies. Our previous work, which used a combinatorial 
analysis of genes most consistently deregulated in individual mice and those reported 
in previous studies, found that only two genes had been consistently reported as 
upregulated in HSC aging. These genes, Neo1 and Spdr, have surprisingly never been 
the focus of hematopoietic stem cell studies.
We decided to focus on Neogenin for multiple reasons. First, it has been previously 
implicated in differentiation, migration, inflammation and proliferation of certain cell 
types 1–6, all processes which are thought to be modulated in HSC aging. Secondly, as 
a transmembrane receptor, it allowed for the isolation and ligand-induced perturbation 
of HSCs based on Neogenin expression for further functional investigation. Thirdly, 
although Neogenin has been associated with LT-HSCs indirectly via gene lists of 
differentially expressed genes enriched in LT-HSCs and a LT-HSC subpopulation 7–12, 
it has never directly been experimentally investigated in this way, and offered some 
novelty.
The structure of Neogenin is highly similar to the tumor suppressor Deleted in 
Colorectal Cancer (DCC).  Neogenin is an extremely large protein (190kDa) 13, and 
contains three structural domains; an extracellular domain consisting of IgG-like 
loops and fibronectin repeats, a transmembrane domain, and an intracellular domain 
through which downstream signaling occurs 14 (Figure 1A). The multifunctional role 
of Neogenin is facilitated by its ability to bind multiple families of ligands, mainly 
Netrins and Repulsive Guidance Molecules (RGMs) 1. RGMs and Neogenin are able 
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to act as co-receptors for BMPs and are thought to enhance BMP signaling in this 
way 15. Different Neogenin ligands (illustrated in Figure 1B) (even within the same 
family) are able to bind distinct sites of the extracellular domain of Neogenin, and this 
is thought to play a role in the different effects these bindings generate. For example, 
during axon development, axons demonstrate chemoattraction towards Netrin-1 but 
chemorepulsion to RGMa 16. Spatially controlled gradients of these two ligands aid 
in the precise localization of axons along the spinal cord. Similarly, embryonic stem 
differentiation has been shown to be delayed by Netrin-1, but accelerated by RGMc 17. 
The intracellular domain of Neogenin has been less characterized than its extracellular 
domain, but has been shown to interact with Focal-adhesion and Src kinase family 
members, in addition to transcription factors Lim-only Binding Protein 4 (LMO4) 
and Nuclear factor of activated T Cells (NFATc3) 2,13,18–20 alluding to the ability of 
Neogenin to not only activate downstream pathways, but also to activate transcription. 
Beyond the interacting partners, the intracellular domain has been reported to have 
transcriptional regulatory activity through translocation to the nucleus 21, and pro-
apoptotic activity brought about by cleavage of its Caspase-3 motif 22,23.
In light of the complexity of Neogenin and its downstream effects, our initial questions 
were straightforward: We wished to investigate whether Neogenin was expressed in 
hematopoietic stem and progenitor cells, to validate its upregulation with HSC aging 
at the RNA and protein level, and to determine if perturbations of Neogenin expression 
could affect HSC function.
Methods
Mice
C57BL/6, C57BL/6.SJL and W41.SJL were obtained from the Central Animal Facility 
(CDP) at the University Medical Center Groningen. All experiments were approved 
by the requisite regulatory authorities.
Mouse HSC and Progenitor Cell Isolation
Bone marrow was isolated from the tibia, femura, pelvis, sternum and spine by crushing, 
and red blood cells were lysed with erylysis buffer. The white blood cells were stained 
with a cocktail of antibodies as follows: antibodies detecting lineage (Lin) markers 
(B220, CD3, Gr-1, Mac-1 and Ter-119) were conjugated with Alexa 700, antibodies 
detecting c-Kit were conjugated with Phycoerythrin, antibodies detecting Sca-1 were 
conjugated with Pacific Blue, antibodies detecting CD48 were conjugated with Alexa 
647, and antibodies detecting CD150 were conjugated with PeCy7, CD16/42 PeCy7, 
CD127 Phycoerythrin and CD34 FITC (all antibodies were purchased from Biolegend). 
These antibodies were used in combination to isolate LT-HSC, ST-HSC and progenitor 
populations as detailed below.
LT-HSCs were characterized as Lin-Sca-1+c-Kit+CD48-CD150+, ST-HSCs as Lin-Sca-
1+c-Kit+CD48-CD150- and MPPs as Lin-Sca-1+c-Kit+CD48+CD150-). For isolation of 




CLP (Lin-CD127+Sca-1loc-Kitlo), CMP (Lin-CD127-Sca-1-c-Kit-CD34+CD16/CD32hi), 
GMP (Lin-CD127-Sca-1-c-Kit+CD16/CD32hi), and MEP (Lin-CD127-Sca-1-c-
Kit+CD34-CD16/CD32+). 












Figure 1 Structure of Neogenin and its 
receptors. A. The Neogenin receptor is part of the 
immunogloubin family of receptors, consisting of 
externally of 4 Immunoglobulin-like (IgG-like) 
residues and 6 Fibronectin III (FnIII) repeats. 
Neogenin’s intracellular and external domains 
are separated by a transmembrane domain. 
The intracellular doman consists of 3 subunits, 
whose residues have been shown to interact with 
signaling activators (e.g. Src kinase and Focal 
adhesion kinase) and transcription factors (e.g 
NFATc3 and LMO4). B. Neogenin ligands consist 
of two familys; Netrins and Repulsive Guidance 
Moclules (RGMs) listed here. Neogenin is also 
able to enhance Bone-morphogenic signaling in 
combination of BMPs and RGM proteins.
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Human CD34 Cell Isolation
Cord blood was obtained from healthy full-term pregnancies after informed consent 
in accordance with the Declaration of Helsinki from the obstetrics department at the 
Isala hospital in Zwolle, the Netherlands. Initially, cord blood volume and cell counts 
were measured and then diluted 1:1 with PBS 2mM EDTA 0.5% BSA. Maximum 
30 ml of diluted cord blood was carefully layered on 15 ml of Lymphoprep™ in a 
50ml falcon tube and centrifuged for 20 minutes, 800g, without brakes. Middle layer 
containing mononuclear cells were harvested and diluted 1:1 with PBS 2mM EDTA 
0.5% BSA and then centrifuged for 5 minutes at 800g. Cell pellets were collected and 
washed with PBS 2mM EDTA 0.5% BSA and centrifuged for 10 minutes at 200g. 
Immunomagnetic labeling and separation was performed according to the manufacture 
manual of the CD34 MicroBead Kit, human (Miltenyi Biotec). Cells were either used 
immediately for experiments or frozen in Cryostor CS10. For isolated of CD34-CD38- 
Neo1+ and Neo1- cells, approximately 1x106 CD34+ enriched cord blood cells were 
blocked for 30 minutes with 4% BSA, washed and stained with CD34 APC, CD38 PE 
(BD Biosciences) and rabbit anti-human Neogenin (Santa Cruz) for 30 minutes at 4°C. 
After washing, cells were stained with 1:100 goat anti-rabbit Alexa 488 (Invitrogen). 
Cells were isolated on Moflo XDP cell sorter (Beckman Coulter). 
For isolation of Bone Marrow CD34+ cells, after achieving informed consent, bone 
marrow aspirates were obtained from patients age >60 years (old) who underwent total 
hip replacement, volunteers age 18 to 35 years (young), and young healthy potential 
donors for hematopoietic Allogenic Stem Cell Transplantation who underwent BM 
aspiration as part of a standard medical examination. The protocol for normal bone 
marrow (NBM) collection was approved by the Institutional Review Board of the 
University Medical Center Groningen. All participants had normal general health and 
normal peripheral blood counts and an absence of hematologic disorders.  Mononuclear 
Cell fraction isolation and immunomagnetic separation of CD34+ cells was performed 
using Lymphoprep™ and CD34 MicroBead Kit, human (Miltenyi Biotec) respectively 
according to manufacturer’s instructions.
qPCR Gene Expression Analysis
At least 10,000 LT-HSC, ST-HSC, MPP, CLP, GMP and MEP were sorted directly 
into lysis buffer and RNA was isolated using the Nucleospin RNA XS Kit (Machery 
Nagel). RNA quality and quantity was determined (Bioanalyzer, Agilent Technologies). 
RNA was reverse transcribed into cDNA with the Superscript VILO cDNA Synthesis 
Kit (Invitrogen). Amplicons for Neogenin and housekeeping gene HPRT were 
amplified and quantified via qPCR using LightCycler SYBR Green I Master mix and 
LightCycler 480 Instrument (Roche). Neogenin expression was normalized relative to 
the housekeeping gene HPRT.
Gene Expression Profiling of Bone marrow CD34+ Cells
Young NBM samples for the microarray analysis came from young healthy volunteers 
and young potential donors. All older NBM samples came from patients undergoing 
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total hip replacement. 
Total RNA was isolated using the RNeasy mini kit from Qiagen according to the 
manufacturer’s recommendations. RNA quality was examined using the Agilent 2100 
Bioanalyzer (Agilent Technologies). Genome-wide expression analysis was performed 
on Illumina (Illumina, Inc.) BeadChip Arrays Sentrix Human-6 (46k probesets). 
Typically, 200 ng of mRNA was used with Illumina Totalprep RNA Amplification 
Kit (Ambion) and 750 ng of cRNA was used in labeling reactions and hybridization 
with the arrays according to the manufacturer’s instructions. Data were analyzed using 
the BeadStudio v3 Gene Expression Module (Illumina, Inc.) and Genespring (Agilent 
Technologies). In total, we analyzed 11 young (age 18-35) and 22 old (age>65) bone 
marrow CD34+ samples.
Immunofluorescence Staining
4000-6000 LT-HSC were seeded onto spots of an immunofluorescent adhesion Slide 
(VWR) and allowed to settle for 20 minutes. Cells were simultaneously fixed and 
permeabilized with Fixation and Permeabilization Solution (BD Biosciences) for 
20 minutes on ice. Cells were then blocked with 4% BSA for 30 minutes at room 
temperature and stained with 1:100 Mouse Neogenin Biotinylated Antibody (R and D 
Systems) and alpha tubulin rabbit anti-mouse antibody Alexa-488 (Abcam) overnight 
at 4°C. Cells were washed three times in 0.1% Tritox-X-100 PBS solution and stained 
with 1:500 secondary antibody streptavidin Alexa-647 for one hour at 4°C. After 
washing, coverslips were mounted with ProLong Diamond Antifade Mountant with 
DAPI (Thermo Fisher). 
Images were acquired on a Leica Sp8 confocal microscope and quantified on Fiji 
Image J.
Intracellular Flow Cytometry 
LT-HSC were fixed and permeabilized using Fixation and Permeabilization Solution 
(BD Biosciences) for 20 minutes at 4°C. Cells were washed twice in 0.1% Triton-X-100 
and blocked with 4% BSA for 30 minutes at room temperature. Cells were stained 
with 1:100 Mouse Neogenin Biotinylated Antibody (RnD Systems) for 1 hour at 4°C. 
Following two washes in 0.1% Triton-X-100, cells were stained with 1:500 secondary 
antibody streptavidin Alexa-647 for 30 minutes at 4°C. Cells were washed in 0.1% 
Triton-X-100 and resuspended in 0.2% PBS/BSA for acquisition. Fluorescence was 
measured on BD FacsCantoII (BD Biosciences) and data analyzed on Flowjo (Flowjo, 
LLC).
HSC Lentiviral Transduction
Neogenin and SCR shRNA plasmid DNA were purchased from Sigma-Aldrich and 
subcloned into PLKO.1 mCherry vector (kindly provided by Dr. Hein Schepers, 
Dept of Hematology, UMCG). For lentivral particle production, HEK293T cells were 
transfected with 3µg plasmid DNA (Neo1 shRNA or SCR control vectors), 0.7µg 
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VSV-G envelope vector, and 3µg packaging construct pCMV8.91 in the presence of 
Fugene HD (Roche). Viral supernatant was collected 24-36 hours later.
For transduction of LT-HSC, purified cells were cultured for 24 hours prior to 
transduction in Stemspan (StemCell Technologies) supplemented with 10% FCS, and 
cytokines 300 ng/mL recombinant mouse Stem Cell Factor (Peprotech), 100ng/mL 
recombinant mouse IL-11 (R&D Systems) and 100ng/mL Flt3 ligand (Amgen). After 
24 hours in culture, LT-HSC and viral supernantant were combined in a retronectine 
(TaKaRa Bio) coated wells and spun for 60 minutes at 400g after which supernatant 
was removed and cells resuspended in fresh media supplemented with cytokines for a 
further 24 hours.
Single Cell Colony Assay
Single LT-HSCs transduced with either Neo1 or SCR shRNA (mCherry+) were 
sorted into the inner 60-wells of round-bottom 96-well plates and cultured for 14 
days in Stemspan (StemCell Technologies) supplemented with 10% FCS, 300ng/ml 
recombinant mouse Stem Cell Factor (Peprotech), 30ng/ml IL-11 (R&D systems) and 
10ng/ml Flt3 ligand (Amgen). Colony sizes were scored at day 14 at 50x magnification 
using an oculair cross on Zeiss Axiovert 25.
Bone Marrow Transplantation and chimerism analysis
Transduced LT-HSC from B6 donor mice were mixed with W41.SJL competitor 
whole bone marrow cells and subsequently transplanted, 24 hours post transduction, 
into lethally irradiated (9Gy) B6.SJL recipients.
For blood chimerism analysis, 250ul of peripheral blood was lysed with erylysis buffer 
and stained for CD45.2 BUV395, CD3 APC, B220 FITC, Gr-1 A700 and Mac-1 A700 
(all from BD Biosciences). Samples were acquired on BD LSRII (BD Biosciences) 
and analyzed on Flowjo (Flowjo LLC).
LTC-IC Assay
The CAFC and LTC-IC assays were performed as previously described 24,25. Limiting 
dilution frequencies were analysed using ELDA 26.
Results
Neogenin is highly expressed in LT-HSC and upregulated in aged Hematopoietic 
Stem Cells 
Our previous global RNA-Seq experiments (Chapter 4) found Neogenin to not only 
be upregulated in our analysis of gene expression changes in Old HSCs compared to 
young (Figure 2B) but to be one of two of the most consistently upregulated genes 
in murine HSC aging. In our investigation of genes upregulated in individual young 
and old mice compared to previously reported studies using pools of mice, not only 




We first wanted to validate these genome-wide RNA-Seq experiments and demonstrate 
that Neogenin was upregulated in HSCs at both the RNA and protein level. Indeed, 
Neogenin RNA expression was significantly upregulated (~5-fold) in old vs young 
HSCs as measured by qPCR analyses on RNA isolated from old or young HSCs 
(Figure 2C). To measure protein expression in individual HSCs, we used intracellular 
flow cytometry (Figure 2D) and confocal microscopy (Figure 2E). Again, Neogenin 
was significantly upregulated in old HSCs compared to young, however at the single 
cell level this was not a global upregulation, as many old HSCs had comparable levels 
to young. Instead there was an emergence of a population of Neogeninhi HSCs in the 
aged HSC pool (Figure 2D). We did observe a difference in polarity, where Neogenin 
had a polarized expression in the majority of young HSCs but was more evenly 
distributed in aged HSCs (polarity observed in 60.7% young HSCs vs. 38.1% aged 
HSCs). 
To gain further insight into the implication of Neogenin upregulation in aged HSCs, 
we wondered how the expression of Neogenin varied in cell types with different 
self-renewal and differentiation potentials. For this reason, we measured Neogenin 
RNA expression among the stem and progenitor compartment, from LT-HSCs with 
enhanced self-renewal and differentiation capabilities, to cell types with reduced 
and no self-renewal (ST-HSC and MPPs respectively) and cell types with lineage-
restricted differentiation (i.e. Common Lymphoid (CLP), Common Myeloid (CMP), 
Megakaryocyte Erythrocyte (MEP) and Granulocyte Macrophage (GMP) progenitors). 
Across the entire hematopoietic tree, Neogenin expression was positively correlated 
with self-renewal potential. LT-HSC expressed highest levels of Neogenin compared 
to all other cell types and expression levels decreased drastically from LT-HSC to 
ST-HSC, and again from ST-HSC to MPP. All committed progenitors expressed 
negligible levels of Neogenin compared to LT-HSC, with no significant differences 
between them (Figure 3A).
Knock-down of Neogenin in Aged HSCs Impairs function in vitro and in vivo
As Neogenin expression is upregulated with age, we questioned whether there 
would be phenotypic consequences of repressing Neogenin in different degrees of 
Neogenin knock-down. One shRNA (Neo1 shRNA 1) resulted in 25% downregulation 
of Neogenin whereas the other (Neo1 shRNA 2) resulted in 80% downregulation 
(Figure 3B). When aged LT-HSCS were lentivirally transduced with these shRNAs 
and their proliferation tested over 14 days via a single-cell colony assay, we saw a 
dose-dependent effect of Neogenin knock-down on HSC proliferation. For both 
shRNAs, knock-down of Neogenin resulted in a reduction of HSC proliferation and 
this reduction of proliferation was dependent on the level of knock-down, with Neo1 
shRNA 2 having the lowest number of HSCs forming colonies and the colonies that 
did grow were significantly smaller than SCR control or Neo1 shRNA 1 (Figure 3C).
To assess the consequences of repressing Neogenin in HSCs to functioning of these 
cells in vivo, we lentivirally transduced LT-HSC with the most potent Neo1 shRNA 
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Figure 2  Neogenin is upregulated in aged HSCs. A. 
Combinatorial analysis of top differentially expressed genes in individual 
aged mice in our data and in other reported studies (including ours). Grey 
bars indicate number of times a gene has been reported by various studies 
8,9,10,11,12  to be differentially expressed in aged HSCs compared to young. 
Boxes under individual mice (designated M1-5) represent significant 
differential expression from average expression in young HSCs. Genes 
are categorized according to the color coding shown at the bottom of the 
figure. B. Normalized counts per million (cpm) of Neogenin expression 
between young and old HSC in our RNA-seq analysis (described in 
Chapter 4). * denotes significant T-test p value (p<0.05).   C. Relative 
Neo1 mRNA expression as analysed by qPCR normalized on the house-
keeping gene HPRT and young expression. * denotes significant T-test p 
value (p<0.05).  D. Neogenin protein expression in young and old HSC 
measured by intracellular flow cytometry. * denotes significant T-test p 
value (p<0.05). E. Confocal images of Neogenin expression in young 
and old HSCs. Scale bar = 5µm.
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(shRNA 2) or with a SCR control vector, and competitively transplanted these cells 
-in vivo into irradiated recipients, using W41.SJL whole bone marrow as competitors. 
All Neogenin knock-down recipients failed to engraft up to 12 weeks (<1% mCherry+ 
peripheral blood cells), in contrast to SCR controls which demonstrated robust 
engraftment (Figure 3D).
Downregulation of Neogenin in Young HSCs has no effect on repopulation 
We next sought to investigate whether the observed effect of Neogenin downregulation 
was specific to aged HSCs. We therefore transduced young LT-HSC (isolated from 4-6 
month old mice) with Neo1 shRNA2 and again, transplanted these cells in vivo into 
irriadiated recipients using W41.SJL whole bone marrow as competitors. Surprisingly, 
young HSCs in which Neogenin expression was repressed were able to engraft and 
contribute to blood production and there was no significant difference between young 
Neo1 knock-down cells and SCR control in vivo in terms of whole blood chimerism 
(mCherry+ cells) (Figure 3F), although they did show a reduction in proliferation in 
vitro (data not shown). Neogenin knock-down HSC displayed some lineage bias in 
repopulation (Figure 3G), although this was not statistically significant at 20-weeks 
post transplantation. 
Neogenin is expressed on a subset of human Umbilical Cord CD34+CD38- HSCs 
and isolated Neohi cells display reduced in vitro functionality
As Neogenin is a transmembrane receptor protein, we sought to isolate HSCs based 
on their Neogenin expression by Fluorescent Activated Cell sorting (FACS) and 
investigate the functional difference between Neohi and Neolo cells. The availability 
of commercial antibodies for Neogenin is sparse, and the only suitable antibody for 
FACS provided detectible signal only human Neogenin. Like murine HSCs, Neogenin 
was also found to be upregulated in human bone-marrow CD34+ Cells (Figure 4A). 
Therefore, we sought to investigate functional differences in Neohi and Neolo cells 
in human HSCs, using cord blood derived HSCs. Human CD34+CD38- cord blood 
cells do express Neogenin and a subset of CD34+CD38- expressed Neogenin to a 
comparably high level, compared to CD34- cells (Figure 4B and C).
To determine whether there was any functional difference between CD34+CD38- 
Neogeninhi and Neogeninlo cells we isolated these subsets from human umbilical cord 
CD34+CD38- cells by FACS and co-cultured them with MS-5 stromal cells in 96-well 
plates. At day 35 wells were scored for the presence of hematopoietic cells, which 
were further categorized into output cell activity (differentiated) or cobblestone-area 
cell forming colony (primitive). While Neogeninlo cells resulted in a majority of wells 
with hematopoietic activity and substantial CAFC activity at day 35, Neogeninhi cells 
had much less or no output or CAFC activity (Figure 4D). 
To further test HSC activity, we subjected these co-cultured cells at day 35 to the LT-IC 
assay by subsequent addition of methylcellulose and cultured them for an additional 
7 days. Newly emerged colonies were scored to determine LT-IC frequency. Again, 
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Figure 3 Functional Analysis of Neogenin Repression. A. Neogenin is preferentially 
expressed in LT-HSC compared to progenitors. Q-PCR analysis of Neogenin expression in the HSPC 
compartment in young mice. LT-HSC = long-term hematopoietic stem cells, ST-HSCs = short-term 
hematopoietic stem cells, MPP = multipotent progenitors, CLP = common lymphoid progenitors, CMP 
= common myeloid progenitors, GMP = granulocyte-macrophage progenitor, MEP = megakaryocyte–
erythroid progenitor. Expression is normalized to housekeeping gene HPRT and on LT-HSC expression. 


























































































































































Figure 4 Functional Analysis of Neohi Subsets in CD34+CD38- Cord Blood. A. 
Neogenin  is upregulated in old human bone-marrow CD34+ cells compared to young. Neogenin 
mRNA expression measured using Illumina BeadChip Array. * denotes significance T-test 
p-value. B. Gating strategy and Neogenin expression in CD34+CD38- and CD34- Cord Blood 
Cells. C. Frequency of Neohi cells in CD34+CD38- and in CD34- cells in 7 individual cord 
blood isolates. D. Day 32 Cobblestone Area Forming Cell Analysis of Neohi cells and Neolo 
CD34+CD38-. E-F. LTC-IC Frequency of Neohi cells and Neolo CD34+CD38-.
normalized to SCR control as measured by qPCR. C. Day 14 single cell colony sizes of LT-HSC 
with Neo1 shRNA 1 and 2 and SCR control.  Cell number of colony sizes indicated on the right. * 
denotes significant p-value as measured by Chi-Square Test. E-F. Whole blood chimerism of in-vivo 
transplantation assay of old (E) and young (F) LT-HSC transduced with Neo1 shRNA2 or SCR control. 
G. Week 20 blood lineage distribution of blood contribution from Neo1 shRNA 2 transduced young 
transplanted HSCs compared to SCR control.
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Discussion
In this study, we selected a gene identified in our previous work as being most 
frequently upregulated in HSC aging and therefore a promising candidate for further 
investigation. The work reported here serves as a proof-of-concept in our approach to 
selecting candidate genes for further investigation. Not only is Neogenin expression 
increased in both human and mouse aged HSCs, but it is highly preferentially 
expressed in the most primitive LT-HSC fraction in both the old and young HSC 
compartment. Previous studies have shown Neogenin expression in progenitors of 
many tissues, including retinal axons, olfactory neuroblasts and embryonic stem cells, 
and its downregulation upon differentiation. In some of these studies, knock-down of 
Neogenin has been shown to result in a block in differentiation. Although Neogenin 
has been thus far regarded mainly as a migratory and neuronal protein, our experiments 
in HSCs and the other studies previously mentioned give strong evidence for a wider 
role of a marker of stem cell potential.
Repression of Neogenin affected young and aged HSCs to different degrees. Although 
both had an effect on proliferation in vitro, only aged HSCs showed reduced chimerism 
upon Neogenin engraftment. In fact, aged HSCs were unable to engraft up to 12-weeks 
post-transplantation. Young HSCs at 20-week post-transplantation had no difference 
in total blood chimerism level, but displayed a slight increase in B cell chimerism. The 
differences we observed in the effect of Neogenin downregulation between young and 
old HSCs was quite interesting and warrants further investigation. Further experiments 
to validate this difference and investigate molecular consequences of Neogenin 
downregulation are underway. It may be that the downregulation of Neogenin pushes 
these cells towards exhaustion. Young stem cells may withstand this longer than 
aged HSCs which are already at a detriment for self-renewal. The transplantation 
assay is notably stressful, requiring homing of cells to the bone marrow, their rapid 
expansion beyond homeostatic levels and simultaneous multilineage differentiation. 
Previous work by us and others have shown that aged HSCs perform poorly at 
competitive transplantation compared to young without any genetic modulation. 
Therefore, it may be plausible that modulation of a gene like Neogenin, which is able 
to regulate migration, proliferation and differentiation may affect aged HSCs to a 
larger degree than young. It is also possible that downregulation of Neogenin could 
affect a subset of HSCs dependent on a Neogenin-regulated pathway, constituting a 
considerably larger proportion of the aged HSC pool compared to young (due to the 
emergence of Neogeninhi population in aged HSCs), and that this could explain the 
larger effect observed in our transplantation assay. This hypothesis is an exciting one, 
as a modulation that selectively affects aged HSCs with little to no consequence to 
young HSCs would be a promising avenue for clinical therapies. We did observe some 
lineage skewing in young HSCs at week 20 upon Neogenin repression, specifically 
an increased contribution to B-cell lineage and decrease in monocytes. Although this 
was not significant, the dynamics of blood repopulation still fluctuate at 20-weeks post 
transplantation and longer-time points are needed to reach a level of consistency. 
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Following the phenotypes observed, we decided to assess the functional characteristics 
of HSCs expressing varying levels of Neogenin. Presently, there is only one Neogenin 
antibody available for fluorescent activated cell sorting of viable cells (required for 
functional assays). In our tests on murine cells, signal from this antibody was only 
observed after fixation and permeabilization of murine cells. We observed no signal 
of this antibody when murine cells were not fixed or permeablized. We did observe 
signal in human Neogenin-expressing cells. The reason for this difference is not yet 
clear to us. Interestingly, a subset of human cord blood HSCs expressed Neogenin to 
a high degree (we termed these Neogeninhi cells). In vitro functional testing of these 
cells revealed them to be markedly lower in both CAFC and LT-IC activity compared 
to Neogeninlo cells. This result was counter-intuitive, as we have seen Neogenin to 
be preferentially expressed in the most primitive cells in mouse. There are some 
considerations to interpret this result. First, it is possible that the use of Neogenin 
antibody for cell sorting may inadvertently serve as a blocking antibody of the receptor 
by blocking residues required for binding or activation. In this scenario, we may not 
have measured Neogeninhi cell function but the result of blocking Neogenin activation. 
It has been reported that Neogenin may function as a death/dependence receptor, 
wherein lack of signaling leads to apoptosis of cells, whereas Neogenin signaling 
maintains survival. Further work is needed to verify that this is not the case. Secondly, 
while the CAFC assay and LT-IC assays are well established methods to measure 
HSC function, their culture conditions confer a myeloid bias. If Neogenin may also 
affect differentiation and may also be associated with T-cells (as has been reported), 
it is possible that Neogenin may mark lymphoid or even T-cell biased HSCs, which 
less frequently differentiate into myeloid lineages measured during this assay. Other 
assays, such as the transplantation assay, allowing for multilineage differentiation 
of human HSCs may be more suitable to measure this. Lastly, we used umbilical 
cord blood HSCs during these assays. Although these are a rich source of functional 
HSCs, they are at a different developmental stage than adult HSCs. Since Neogenin is 
upregulated with age in both human and mouse HSCs, adult bone marrow or mobilized 
HSCs might contain a larger population of Neogeninhi HSCs which contain different 
functional characteristics than their fetal counterparts.
Our data show that Neogenin expression is enriched in long-term HSCs and variations 
in its degree of expression mark HSC subsets with different stem cell potential. 
Knock-down of Neogenin leads to the amelioration of HSC engraftment in aged 
HSCs. Further investigation is needed into molecular differences between Neogeninhi 
and Neogeninlo HSCs. Considering its role in development of many tissues, a reporter 
or tissue specific conditional knock-out mouse may be beneficial to investigate at 
what stages Neogenin expression is upregulated. The possibility of isolating HSCs 
based on their expression of Neogenin is an exciting one which may pave the way for 
clinical therapy. Generation of a murine specific antibody for the external residues of 
Neogenin suitable for FACS would advance investigation into this approach, as the 
mouse has been an invaluable tool in HSC experimentation. This would allow the 
investigation of transplantation of Neogeninhi and lo HSCs, the consequence of their 
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selective depletion and the effect of Neogenin blocking antibodies on HSC function 
and aging.
HSC biology is well regulated and its aging phenotypes have been well documented, 
but are complex in nature. For example, the aged HSC pool undergoes dramatic 
expansion during aging but the functioning of old HSCs is reduced and they acquire the 
tendency to be myeloid biased. Aged HSCs have also been shown to be differentially 
located in the niche and have reduced homing potential. Within the umbrella that 
we term HSC aging there are many mechanisms and phenotypes involved. Many 
candidate genes investigated regulate a subset of these phenotypes, e.g. inflammation, 
proliferation or self-renewal. Neogenin stands out for its ability to be multifunctional 
and it is likely that such a multifunctional receptor may contribute in many ways to the 
multifaceted aging phenotypes observed. From our investigations, it is also likely that 
Neogenin affects HSC function not just in aged HSCs, but within LT-HSCs largely. 
This study therefore highlights Neogenin as a promising candidate for HSC aging and 
HSC biology.
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